Among the subtypes, triple-negative breast cancer (TNBC), which is defined by the lack of ER and PR expression and the absence of HER2 amplification, accounts for 10–20% of annually diagnosed breast cancer cases [4]. This evidence concerns the gene ESR1 and breast cancer.